Prices, availability, and affordability of selected medicines for asthma management in Nigeria: a nationwide study Authors: Kosisochi Chinwendu Amorha, Faith Nnenna Eze, Ifeoma Felicita Uzuh, Somtochi Prosper Nwani, Jennifer Chigozie Iganga, Chidera Edith Eze, Chukwudi Richard Ifeanyi, Adaora Anthonia Agubata, Chisom Sandra Ibenekwu, Immaculata Chidimma Aniebonam, Angela Chinasa Ani, Chinelo Cynthia Ezenwafor, Emelda Chinemerem Omene, Oluoma Maryjane Chukwuwa, Chisom Peace Ezeala, Chidimma Elizabeth Mbakamma, Chinagozim Rufina Nworah, Mmaduabuchi Desmond Udoji, Kossy Maryann Ochie, Ruth Nkechi Sabastine, Ogechi Christiana Obi, Rita Nnenne Oparaocha, Chibueze Raymond Okoye, Oluebubechukwu Praise Eze Published: 2025 ABSTRACT BackgroundRecent inflation in Nigeria could hinder access to medicines. The aim of the study was to evaluate the prices, availability, and affordability of selected medicines for asthma management in Nigeria.MethodsThis cross-sectional survey (January 2024 – March 2024) was conducted in community pharmacies in the six geopolitical zones of Nigeria. Data for Originator Brand (OB) and Lowest-Priced Generic (LPG) were collected with the Medicine Price Data Collection Form developed by the World Health Organization/Health Action International (WHO/HAI). Twenty-three (23) selected medicines for asthma management were utilised. The Median Price Ratio (MPR) was the ratio of the median local unit price to the international reference unit price (IRP). The IRPs were South African government procurement prices. Availability was reported as the percentage of medicine outlets in which the medicine was found on the day of data collection. Affordability was the number of days of work by the lowest-paid unskilled national government worker to purchase a defined course of treatment for a specific condition.ResultsOf the 300 community pharmacies that were sampled, 214 responses were retrieved (participation rate: 71.3%). The majority of the medicines (n = 18 of 21, 85.7%) were more than two times the international reference unit prices (IRPs). Salbutamol 100 mcg inhaler Originator Brand (OB) was 11.8 times the IRP, while the Lowest-Priced Generic (LPG) was 5.3 times the IRP. The average per cent availability across OBs (11.2%), LPGs (18.8%), and all medicines (15.0%) was less than 50%. The majority of the medicines (n = 36 of 39, 92.3%) cost more than a day’s wages. Salmeterol 25 mcg/Fluticasone 125 mcg inhaler would require 31.0 days’ wages with OB and 9.5 days’ wages with LPG.ConclusionsThe findings reveal high medicine prices, poor availability, and low affordability of asthma medicines. There is a need for targeted subsidies on medicines for the management of asthma, insurance reforms, and local manufacturing incentives. Background Asthma is a chronic respiratory disease that affects the airways [1]. Globally, asthma is the most common respiratory disease with a significant clinical and economic burden on patients, families, and communities [2]. The prevalence of asthma in Nigeria is high with variabilities across regions and age groups [3]. Asthma could affect quality of life through social, emotional, physical, and occupational impacts [4]. Since there is no cure for asthma, the management aims to achieve good control of symptoms, maintain normal activity levels, and minimise future risk of exacerbations [5]. Poor asthma control is consistently linked to increased morbidity and mortality, emphasising the need for research and interventions to address this pressing global health problem [6]. A third of the global population lacks access to needed medicines [7]. While effective asthma medications are available, high costs and limited availability in facilities could pose significant challenges to asthma management, particularly in low- and middle-income countries (LMICs) [8, 9]. Treatment challenges in managing asthma include the high cost and unavailability of essential asthma medications [10]. The economic burden of asthma is borne by families without social health insurance in LMICs, unlike in countries where well-structured insurance schemes ease the asthma burden on households by covering some investigations and treatments [11]. The cost of asthma medications in Nigeria, and the poor income of many Nigerians, coupled with the lack of health insurance coverage, make it difficult for many Nigerians to access and afford essential medicines [12]. LMICs have been documented to have the highest mortality from asthma and chronic obstructive pulmonary disease (COPD) [13]. It has been reported that the availability and affordability of essential medicines for treating asthma and COPD in LMICs are inadequate [13]. High medicine prices and low affordability hinder access to treatment in LMICs, especially in countries where the majority of the population purchases medicines through out-of-pocket payments [14]. Availability and affordability are the commonly explored dimensions of access to medicines [15]. Poor affordability and poor access to medicines can lead to non-adherence [7]. Several factors have been documented as contributors to the limited availability of asthma medications in Nigeria. These factors include limited local production, inadequate funding to aid the subsidy of these medications, poor distribution systems, lack of health insurance coverage, and limited education and awareness [12]. In LMICs, essential medicines for the treatment of asthma are neither available nor affordable [13]. Due to the increasing disease burden, it is a priority to address access to these essential medicines for asthma [13]. With the recent hikes in prices and the attendant effects on patients managing asthma, it is necessary to conduct a study to evaluate the prices, availability, and affordability of selected medicines for asthma management in Nigeria. Methods Study design/setting This cross-sectional survey (January 2024 – February 2024) was conducted in the six geopolitical zones in Nigeria. Nigeria is in the Sub-Saharan Africa WHO Region. The survey areas were Lagos State (South-West), Rivers State (South-South), Anambra State (South-East), Abuja (North-Central), Kaduna State (North-West), and Gombe State (North-East). These survey areas were purposively selected due to the high level of community pharmacy presence in these States. The geographical distribution of the population was considered to ensure that both urban and rural areas were surveyed. Socio-economic status, e.g., low-, medium-, or high-income, was also considered. Thus, in each survey area (State), the sampling frame comprised a list of community pharmacies that reflected a mix of urban, peri-urban, and/or rural areas. The Median Price Ratio (MPR) is the ratio of the median local unit price to the international reference unit price [12]. Availability compares the quantity of medicine required with its presence at health facilities [15]. According to the World Health Organization/Health Action International (WHO/HAI) database of medicine prices, availability, affordability, and price components, the availability of individual medicines is reported as the percentage of medicine outlets in which the medicine was found on the day of data collection [16]. Summary data for availability is presented as either the median or mean availability of the medicines in the selected basket [16]. Affordability refers to a medicine’s price relative to an individual or household’s ability to pay [17]. Affordability is the cost of treatment in relation to people’s income [16]. It is the number of days of work by the lowest-paid unskilled national government worker to purchase a defined course of treatment for a specific condition [16]. The World Health Organization/Health Action International (WHO/HAI) protocol prerequisites for conducting a medicine survey from pre-survey preparation to planning and preparation for data collection, through data collection, data entry, analysis, and interpretation, were adhered to. Private-sector patient prices from licensed community pharmacies were utilised. For each medicine surveyed, the originator brand and lowest-priced generic products were identified at individual community pharmacies. Prices and availability were collected for two products: the originator brand and the lowest-priced generic equivalent. While originator brand products are standard for the country and do not vary from outlet to outlet, the lowest-priced generic equivalent could vary from outlet to outlet, depending on which generic products are available. Ethical clearance Ethical clearance was received from the Health Research Ethics Committee (HREC), University of Nigeria Teaching Hospital (UNTH), Ituku-Ozalla, Enugu State (NHREC/05/01/2008B-FWA00002458-1RB00002323 with reference UNTH/HREC/2024/01/546 on 26 January 2024). The Superintendent Pharmacists of the different community pharmacies were informed before the survey was conducted. The identity of the community pharmacies was kept confidential. Eligibility criteria Only community pharmacies in the six purposively sampled States were included in the study. Sample size and selection Using systematic sampling, 50 community pharmacies were sampled from each of the six States (Lagos, Rivers, Anambra, Abuja, Kaduna, and Gombe). In each survey area (State), the sampling frame comprised a list of community pharmacies that reflected a mix of urban, peri-urban, and/or rural areas. The researchers randomly selected outlets from each list. The researchers created a contact list of the community pharmacies that were to be surveyed. Data collection Data collection was via the Medicine Price Data Collection Form developed by WHO/HAI. The Medicine Price Data Collection Form requested information on generic name, dosage form, strength, medicine type, brand product name(s), manufacturer, availability, recommended pack size, available pack size, price of pack found, and unit price (four decimal places). Survey personnel were familiar with the locality and local language/dialect. Data were collected on the same dosage form and strength in all community pharmacies so that results were comparable. In addition, each medicine had a recommended pack size, which generally corresponds to a standard course of treatment. When a medicine was available in multiple pack sizes, data were collected on the recommended pack size, or if this was not available, on the next largest pack size. This counteracts price differences arising from economies of scale (i.e., lower unit prices offered for larger pack sizes). The survey medicines were selected based on evidence-based medicine (such as first-line courses of treatment in global, regional, and national treatment guidelines), availability (widely used in Nigeria as demonstrated by previously conducted drug utilisation studies), importance (included in the global core list, WHO Model List of Essential Medicines, and National Essential Medicines List), and International Reference Price (South African government procurement prices available in the Master Health Product List will be used as the International Reference Prices). All data were with reference to the day of the survey. The exchange rate on the first day of data collection (29 January 2024) was 1.00 United States Dollar (USD) to 889.423 Nigerian Naira (NGN) and 1.00 South African Rand (ZAR) to 47.3939 NGN, as obtained from the Central Bank of Nigeria (CBN) website [18]. Data analysis Data were analysed using IBM SPSS Version 29.0. Descriptive statistics were used to summarise data, based on the WHO/HAI recommendations. For the medicine prices, the median prices of individual medicines, ratios of median local price to international reference price (MPR), median MPR across a group of medicines, and variations between product types (originator brand versus lowest-priced generic) were determined. For medicine availability, the percent availability of individual medicines, the mean (average) percent (%) availability across a group of medicines, and variations between product types (Originator Brand versus Generic) were determined. Treatment affordability was in relation to the daily wage of the lowest-paid unskilled government worker. Given that price data can quickly become out-of-date, the survey report was generated within one month of completing the data collection/analysis. Results Of the 300 community pharmacies that were sampled, 214 responses were retrieved (participation rate: 71.3%). The highest participation rates were recorded for Abuja (n = 46, 21.5%) and Rivers State (n = 42, 19.6%), Fig. 1.Fig. 1Survey areas, N = 214 Survey areas, N = 214 The majority of the medicines (n = 18 of 21, 85.7%) were more than two times the International Reference Prices (IRPs). Salbutamol 100 mcg inhaler Originator Brand (OB) was 11.8 times the IRP, while the Lowest-Priced Generics (LPG) was 5.3 times the IRP, Table 1.Table 1Prices of selected asthma medicines, n = 214Generic name, dosage form, strengthMedicine TypeMedian Local Unit Price (NGN) – AInternational Reference Unit Price (NGN) – BMedian Price Ratio (MPR) ( = A/B)MPROB/MPRLPGAminophylline injection 250 mg/10 mLOriginator brand350.0000169.19622.06861.7499Lowest-priced generic200.0000169.19621.1821Salbutamol 100 mcg inhalerOriginator brand49.50004.168311.87532.2500Lowest-priced generic22.00004.16835.2779Montelukast 4 mg chewable tabletOriginator brand223.214362.38463.57801.7171Lowest-priced generic130.000062.38462.0838Montelukast 5 mg tabletOriginator brand196.428065.81592.98451.2277Lowest-priced generic160.000065.81592.4310Montelukast 10 mg tabletOriginator brand208.333345.15214.61401.4581Lowest-priced generic142.875145.15213.1643Salmeterol + Fluticasone 25/50 mcg inhalerOriginator brand266.666721.125812.62280.9846Lowest-priced generic270.833321.125812.8200Salmeterol + Fluticasone 25/125 mcg inhalerOriginator brand258.3333***Lowest-priced generic79.1667**Salmeterol + Fluticasone 25/250 mcg inhalerOriginator brand416.666739.905710.44134.2017Lowest-priced generic99.166539.90572.4850Salmeterol + Fluticasone 50/100 mcg Diskus (dry powder inhaler) *Originator brand670.0000***Lowest-priced genericNA**Lowest-priced generic75.4167**Salmeterol + Fluticasone 50/250 mcg Diskus (dry powder inhaler) *Originator brand583.3300***Lowest-priced genericNA**Salmeterol + Fluticasone 50/500 mcg Diskus (dry powder inhaler) *Originator brand850.0000***Lowest-priced genericNA**Formoterol + Budesonide Inhaler (80/4.5) *Originator brand200.1667***Lowest-priced genericNA**Formoterol + Budesonide inhaler (160/4.5) *Originator brand270.000046.97685.7475*Lowest-priced genericNA46.9768*Formoterol + Budesonide inhaler (200/6)Originator brand198.3333***Lowest-priced generic145.8300**Budesonide 180mcg inhaler *Originator brand279.5833***Lowest-priced genericNA**Salbutamol 5 mg nebule *Originator brand650.0000***Lowest-priced generic850.0000**Salbutamol 2.5 mg nebule *Originator brand475.0000***Lowest-priced generic400.0000**Ipratropium 20mcg inhaler *Originator brand60.0000***Lowest-priced genericNA**Lowest-priced generic75.4167**Prednisolone 5 mg tabletOriginator brand80.00008.88649.00254.0000Lowest-priced generic20.00008.88642.2506Adrenaline (Epinephrine) injection 1 mg/mLOriginator brand510.0000189.57562.69022.5500Lowest-priced generic200.000189.57561.0550Azithromycin 250 mg tablet **Originator Brand1900.0000***Lowest-priced generic333.3333**Hydrocortisone injection 100 mgOriginator brand6000.0000823.23207.288315.0000Lowest-priced generic400.0000823.23200.4859Fluticasone 125mcg inhaler *Originator Brand195.0000***Lowest-priced generic75.4167*** Not available in the Master Health Product List**Available in the Master Health Product List in a strength of 500 mg (x 3 tablets and ×2 tablets)MPR = Median Price Ratio, OB = Originator Brand, LPG = Lowest-priced generic Table 1Prices of selected asthma medicines, n = 214Generic name, dosage form, strengthMedicine TypeMedian Local Unit Price (NGN) – AInternational Reference Unit Price (NGN) – BMedian Price Ratio (MPR) ( = A/B)MPROB/MPRLPGAminophylline injection 250 mg/10 mLOriginator brand350.0000169.19622.06861.7499Lowest-priced generic200.0000169.19621.1821Salbutamol 100 mcg inhalerOriginator brand49.50004.168311.87532.2500Lowest-priced generic22.00004.16835.2779Montelukast 4 mg chewable tabletOriginator brand223.214362.38463.57801.7171Lowest-priced generic130.000062.38462.0838Montelukast 5 mg tabletOriginator brand196.428065.81592.98451.2277Lowest-priced generic160.000065.81592.4310Montelukast 10 mg tabletOriginator brand208.333345.15214.61401.4581Lowest-priced generic142.875145.15213.1643Salmeterol + Fluticasone 25/50 mcg inhalerOriginator brand266.666721.125812.62280.9846Lowest-priced generic270.833321.125812.8200Salmeterol + Fluticasone 25/125 mcg inhalerOriginator brand258.3333***Lowest-priced generic79.1667**Salmeterol + Fluticasone 25/250 mcg inhalerOriginator brand416.666739.905710.44134.2017Lowest-priced generic99.166539.90572.4850Salmeterol + Fluticasone 50/100 mcg Diskus (dry powder inhaler) *Originator brand670.0000***Lowest-priced genericNA**Lowest-priced generic75.4167**Salmeterol + Fluticasone 50/250 mcg Diskus (dry powder inhaler) *Originator brand583.3300***Lowest-priced genericNA**Salmeterol + Fluticasone 50/500 mcg Diskus (dry powder inhaler) *Originator brand850.0000***Lowest-priced genericNA**Formoterol + Budesonide Inhaler (80/4.5) *Originator brand200.1667***Lowest-priced genericNA**Formoterol + Budesonide inhaler (160/4.5) *Originator brand270.000046.97685.7475*Lowest-priced genericNA46.9768*Formoterol + Budesonide inhaler (200/6)Originator brand198.3333***Lowest-priced generic145.8300**Budesonide 180mcg inhaler *Originator brand279.5833***Lowest-priced genericNA**Salbutamol 5 mg nebule *Originator brand650.0000***Lowest-priced generic850.0000**Salbutamol 2.5 mg nebule *Originator brand475.0000***Lowest-priced generic400.0000**Ipratropium 20mcg inhaler *Originator brand60.0000***Lowest-priced genericNA**Lowest-priced generic75.4167**Prednisolone 5 mg tabletOriginator brand80.00008.88649.00254.0000Lowest-priced generic20.00008.88642.2506Adrenaline (Epinephrine) injection 1 mg/mLOriginator brand510.0000189.57562.69022.5500Lowest-priced generic200.000189.57561.0550Azithromycin 250 mg tablet **Originator Brand1900.0000***Lowest-priced generic333.3333**Hydrocortisone injection 100 mgOriginator brand6000.0000823.23207.288315.0000Lowest-priced generic400.0000823.23200.4859Fluticasone 125mcg inhaler *Originator Brand195.0000***Lowest-priced generic75.4167*** Not available in the Master Health Product List**Available in the Master Health Product List in a strength of 500 mg (x 3 tablets and ×2 tablets)MPR = Median Price Ratio, OB = Originator Brand, LPG = Lowest-priced generic Prices of selected asthma medicines, n = 214 * Not available in the Master Health Product List **Available in the Master Health Product List in a strength of 500 mg (x 3 tablets and ×2 tablets) MPR = Median Price Ratio, OB = Originator Brand, LPG = Lowest-priced generic The majority of the medicines (36 of 46) had less than 25% availability, Table 2.Table 2Availability of selected asthma medicines, n = 214Generic name, dosage form, strengthMedicine TypeNumber of Outlets with Available MedicinePer cent (%) AvailabilityAminophylline injection 250 mg/10 mLOriginator brand2310.7Lowest-priced generic8941.6Salbutamol 100mcg inhalerOriginator brand9946.3Lowest-priced generic15170.6Montelukast 4 mg chewable tabletOriginator brand62.8Lowest-priced generic4822.4Montelukast 5 mg tabletOriginator brand52.3Lowest-priced generic8137.9Montelukast 10 mg tabletOriginator brand73.3Lowest-priced generic9343.5Salmeterol + Fluticasone 25/50 mcg inhalerOriginator brand198.9Lowest-priced generic20.9Salmeterol + Fluticasone 25/125 mcg inhalerOriginator brand167.5Lowest-priced generic125.6Salmeterol + Fluticasone 25/250 mcg inhalerOriginator brand136.1Lowest-priced generic83.7Salmeterol + Fluticasone 50/100 mcg Diskus (dry powder inhaler)Originator brand20.9Lowest-priced generic00.0Salmeterol + Fluticasone 50/250 mcg Diskus (dry powder inhaler)Originator brand3315.4Lowest-priced generic00.0Salmeterol + Fluticasone 50/500 mcg Diskus (dry powder inhaler)Originator brand83.7Lowest-priced generic00.0Lowest-priced generic20.9Formoterol + Budesonide Inhaler (80/4.5)Originator brand209.3Lowest-priced generic00.0Formoterol + Budesonide inhaler (160/4.5)Originator brand2511.7Lowest-priced generic00.0Formoterol + Budesonide inhaler (200/6)Originator brand94.2Lowest-priced generic73.3Budesonide 180mcg inhalerOriginator brand115.1Lowest-priced generic00.0Salbutamol 5 mg nebuleOriginator brand2612.1Lowest-priced generic2511.7Salbutamol 2.5 mg nebuleOriginator brand7334.1Lowest-priced generic52.3Ipratropium 20mcg inhalerOriginator brand41.9Lowest-priced generic00.0Prednisolone 5 mg tabletOriginator brand10.5Lowest-priced generic17380.8Adrenaline (Epinephrine) injection 1 mg/mLOriginator brand62.8Lowest-priced generic3616.8Azithromycin 250 mg tabletOriginator Brand12658.9Lowest-priced generic10549.1Hydrocortisone injection 100 mgOriginator brand10.5Lowest-priced generic8640.2Fluticasone 125mcg inhalerOriginator Brand198.9Lowest-priced generic20.9 Table 2Availability of selected asthma medicines, n = 214Generic name, dosage form, strengthMedicine TypeNumber of Outlets with Available MedicinePer cent (%) AvailabilityAminophylline injection 250 mg/10 mLOriginator brand2310.7Lowest-priced generic8941.6Salbutamol 100mcg inhalerOriginator brand9946.3Lowest-priced generic15170.6Montelukast 4 mg chewable tabletOriginator brand62.8Lowest-priced generic4822.4Montelukast 5 mg tabletOriginator brand52.3Lowest-priced generic8137.9Montelukast 10 mg tabletOriginator brand73.3Lowest-priced generic9343.5Salmeterol + Fluticasone 25/50 mcg inhalerOriginator brand198.9Lowest-priced generic20.9Salmeterol + Fluticasone 25/125 mcg inhalerOriginator brand167.5Lowest-priced generic125.6Salmeterol + Fluticasone 25/250 mcg inhalerOriginator brand136.1Lowest-priced generic83.7Salmeterol + Fluticasone 50/100 mcg Diskus (dry powder inhaler)Originator brand20.9Lowest-priced generic00.0Salmeterol + Fluticasone 50/250 mcg Diskus (dry powder inhaler)Originator brand3315.4Lowest-priced generic00.0Salmeterol + Fluticasone 50/500 mcg Diskus (dry powder inhaler)Originator brand83.7Lowest-priced generic00.0Lowest-priced generic20.9Formoterol + Budesonide Inhaler (80/4.5)Originator brand209.3Lowest-priced generic00.0Formoterol + Budesonide inhaler (160/4.5)Originator brand2511.7Lowest-priced generic00.0Formoterol + Budesonide inhaler (200/6)Originator brand94.2Lowest-priced generic73.3Budesonide 180mcg inhalerOriginator brand115.1Lowest-priced generic00.0Salbutamol 5 mg nebuleOriginator brand2612.1Lowest-priced generic2511.7Salbutamol 2.5 mg nebuleOriginator brand7334.1Lowest-priced generic52.3Ipratropium 20mcg inhalerOriginator brand41.9Lowest-priced generic00.0Prednisolone 5 mg tabletOriginator brand10.5Lowest-priced generic17380.8Adrenaline (Epinephrine) injection 1 mg/mLOriginator brand62.8Lowest-priced generic3616.8Azithromycin 250 mg tabletOriginator Brand12658.9Lowest-priced generic10549.1Hydrocortisone injection 100 mgOriginator brand10.5Lowest-priced generic8640.2Fluticasone 125mcg inhalerOriginator Brand198.9Lowest-priced generic20.9 Availability of selected asthma medicines, n = 214 The average per cent availability across OBs (11.2%), LPGs (18.8%), and all medicines (15.0%) was less than 20%, Fig. 2.Fig. 2Average per cent availability of medicines, N = 214 Average per cent availability of medicines, N = 214 The majority of the medicines (n = 36 of 39, 92.3%) cost more than a day’s wages. Salmeterol 25 mcg/Fluticasone 125 mcg inhaler would require 31.0 days’ wages with OB and 9.5 days’ wages with LPG, Table 3.Table 3Affordability of selected asthma medicines, n = 214Generic Name, Dosage form, StrengthMedicine TypeMedian Local Unit Price (NGN) – ANumber of Units in a Standard Course of Treatment – BDaily wage of the lowest-paid government worker (NGN) – CDays’ Wages [(A x B)/C]Aminophylline injection 250 mg/10 mLOriginator brand350.00001010003.5Lowest-priced generic200.00001010002.0Salbutamol 100mcg inhalerOriginator brand49.500020010009.9Lowest-priced generic22.000020010004.4Montelukast 4 mg chewable tabletOriginator brand223.21432810006.3Lowest-priced generic130.00002810003.6Montelukast 5 mg tabletOriginator brand196.42802810005.5Lowest-priced generic160.00002810004.5Montelukast 10 mg tabletOriginator brand208.33332810005.8Lowest-priced generic142.87512810004.0Salmeterol + Fluticasone 25/50 mcg inhalerOriginator brand266.6667120100032.0Lowest-priced generic270.8333120100032.5Salmeterol + Fluticasone 25/125 mcg inhalerOriginator brand258.3333120100031.0Lowest-priced generic79.166712010009.5Salmeterol + Fluticasone 25/250 mcg inhalerOriginator brand416.6667120100050.0Lowest-priced generic99.1665120100011.9Salmeterol + Fluticasone 50/100 mcg Diskus (dry powder inhaler)Originator brand670.000060100040.2Lowest-priced genericNA601000*Salmeterol + Fluticasone 50/250 mcg Diskus (dry powder inhaler)Originator brand583.330060100035.0Lowest-priced genericNA601000*Salmeterol + Fluticasone 50/500 mcg Diskus (dry powder inhaler)Originator brand850.000060100051.0Lowest-priced genericNA601000*Formoterol + Budesonide Inhaler (80/4.5)Originator brand200.1667120100024.0Lowest-priced genericNA1201000*Formoterol + Budesonide inhaler (160/4.5)Originator brand270.0000120100032.4Lowest-priced genericNA1201000*Formoterol + Budesonide inhaler (200/6)Originator brand198.3333120100023.8Lowest-priced generic145.8300120100017.5Budesonide 180mcg inhalerOriginator brand279.5833120100033.5Lowest-priced genericNA1201000*Salbutamol 5 mg nebuleOriginator brand650.000020100013.0Lowest-priced generic850.000020100017.0Salbutamol 2.5 mg nebuleOriginator brand475.00002010009.5Lowest-priced generic400.00002010008.0Ipratropium 20mcg inhalerOriginator brand60.0000200100012.0Lowest-priced genericNA2001000*Prednisolone 5 mg tabletOriginator brand80.000010010008.0Lowest-priced generic20.000010010002.0Adrenaline (Epinephrine) injection 1 mg/mLOriginator brand510.0000110000.5Lowest-priced generic200.000110000.2Azithromycin 250 mg tabletOriginator Brand1900.00006100011.4Lowest-priced generic333.3333610002.0Hydrocortisone injection 100 mgOriginator brand6000.0000110006.0Lowest-priced generic400.0000110000.4Fluticasone 125mcg inhalerOriginator Brand195.0000120100023.4Lowest-priced generic75.416712010009.1* Not calculated since there is no Median Local Unit Price Table 3Affordability of selected asthma medicines, n = 214Generic Name, Dosage form, StrengthMedicine TypeMedian Local Unit Price (NGN) – ANumber of Units in a Standard Course of Treatment – BDaily wage of the lowest-paid government worker (NGN) – CDays’ Wages [(A x B)/C]Aminophylline injection 250 mg/10 mLOriginator brand350.00001010003.5Lowest-priced generic200.00001010002.0Salbutamol 100mcg inhalerOriginator brand49.500020010009.9Lowest-priced generic22.000020010004.4Montelukast 4 mg chewable tabletOriginator brand223.21432810006.3Lowest-priced generic130.00002810003.6Montelukast 5 mg tabletOriginator brand196.42802810005.5Lowest-priced generic160.00002810004.5Montelukast 10 mg tabletOriginator brand208.33332810005.8Lowest-priced generic142.87512810004.0Salmeterol + Fluticasone 25/50 mcg inhalerOriginator brand266.6667120100032.0Lowest-priced generic270.8333120100032.5Salmeterol + Fluticasone 25/125 mcg inhalerOriginator brand258.3333120100031.0Lowest-priced generic79.166712010009.5Salmeterol + Fluticasone 25/250 mcg inhalerOriginator brand416.6667120100050.0Lowest-priced generic99.1665120100011.9Salmeterol + Fluticasone 50/100 mcg Diskus (dry powder inhaler)Originator brand670.000060100040.2Lowest-priced genericNA601000*Salmeterol + Fluticasone 50/250 mcg Diskus (dry powder inhaler)Originator brand583.330060100035.0Lowest-priced genericNA601000*Salmeterol + Fluticasone 50/500 mcg Diskus (dry powder inhaler)Originator brand850.000060100051.0Lowest-priced genericNA601000*Formoterol + Budesonide Inhaler (80/4.5)Originator brand200.1667120100024.0Lowest-priced genericNA1201000*Formoterol + Budesonide inhaler (160/4.5)Originator brand270.0000120100032.4Lowest-priced genericNA1201000*Formoterol + Budesonide inhaler (200/6)Originator brand198.3333120100023.8Lowest-priced generic145.8300120100017.5Budesonide 180mcg inhalerOriginator brand279.5833120100033.5Lowest-priced genericNA1201000*Salbutamol 5 mg nebuleOriginator brand650.000020100013.0Lowest-priced generic850.000020100017.0Salbutamol 2.5 mg nebuleOriginator brand475.00002010009.5Lowest-priced generic400.00002010008.0Ipratropium 20mcg inhalerOriginator brand60.0000200100012.0Lowest-priced genericNA2001000*Prednisolone 5 mg tabletOriginator brand80.000010010008.0Lowest-priced generic20.000010010002.0Adrenaline (Epinephrine) injection 1 mg/mLOriginator brand510.0000110000.5Lowest-priced generic200.000110000.2Azithromycin 250 mg tabletOriginator Brand1900.00006100011.4Lowest-priced generic333.3333610002.0Hydrocortisone injection 100 mgOriginator brand6000.0000110006.0Lowest-priced generic400.0000110000.4Fluticasone 125mcg inhalerOriginator Brand195.0000120100023.4Lowest-priced generic75.416712010009.1* Not calculated since there is no Median Local Unit Price Affordability of selected asthma medicines, n = 214 * Not calculated since there is no Median Local Unit Price Discussion The findings reveal high medicine prices, poor availability, and low affordability of asthma medicines. Most of the drugs cost more than twice the International Reference Prices (IRPs). On average, less than 50% of Originator Brands (OBs), Lowest-Priced Generics (LPGs), and all medicines were available. As observed, most medications cost more than a day’s wages. Prices/Cost The medicine price ratio (MPR), an expression of how much greater or less the local medicine price is than the international reference price, was used to compare the local unit prices and international unit prices of various asthma medications sold in Nigeria according to the WHO/HAI protocol prerequisites for conducting a medicine survey [19]. Generally, an MPR of one or less is interpreted as efficient procurement in the public sector, while an MPR below three is considered acceptable for the private sector [20]. However, for this study, only privately owned community pharmacies were assessed. Findings from this study reveal that the Originator Brands (OBs) of all the medications had a significantly higher MPR compared to the Lowest-Priced Generics (LPGs). The majority of the medicines were priced more than twice the IRPs. Similarly, in an analysis of medicine affordability, availability, and pricing across 54 low-income and middle-income countries, patients were required to pay 3.0–11.5 times international reference prices for the lowest-priced generic medicines and over 25 times international reference prices for originator products across all WHO regions [21]. A study conducted across 72 low-, middle-, and high-income markets found large differences in prices and affordability of medicines across markets. When adjusting for the purchasing power of different countries, there was an inverse association between drug prices and country income levels, suggesting that richer countries had lower real prices [22]. Our study revealed unacceptably high MPRs for the OB and LPG of Salbutamol 100 mcg Inhaler and Salmeterol/Fluticasone 25/50 mcg inhaler. Additionally, for other dosage forms, Prednisolone 5 mg tablet and Hydrocortisone injection 100 mg showed significantly high MPRs for the OBs compared to their LPGs, which were relatively low and had acceptable MPRs ( < 3) [20]. These findings were mainly observed for the GlaxoSmithKline (GSK) and Pfizer-based originator brands. High import tariffs, observable decline in the value of the Naira due to foreign exchange crises, and a high rate of inflation have made Nigeria unfavourable for big pharmaceutical companies, ultimately resulting in an exodus of multinational pharmaceutical companies [21]. Consequently, these account for the spike in drug prices in Nigeria [23]. There are concerns about price increases among generics that have few therapeutic competitors and may therefore enjoy some market exclusivity, such as Salmeterol/Fluticasone 25/50 mcg, whose OB and LPG have almost the same median local unit price range [24]. The significant decrease in the availability of OB brands is attributable to inadequate competition by generic manufacturers, production monopolies, and inefficient drug distribution networks [25]. The brand/generic competition often sees a dramatic reduction in price following the arrival of generics onto the market, with prices of oral medicines falling to around 50% of the cost of the branded product within six months of generic introduction [26] .However, the entry of generic competitors is usually limited by high start-up costs, approval requirements, and other legal policies that restrict manufacturers from producing the same formulations [27]. These actions could lead to illegal and unregulated price increases for these scarce generic drugs by unscrupulous pharmaceutical companies taking advantage of the scarcity to price-gouge available LPGs, as noted in this study [28]. Many medicines lacked IRPs, limiting price ratio analysis. Availability The Lowest-Priced Generics (LPGs) for inhaled salbutamol, montelukast, prednisolone, and aminophylline were readily available in the community pharmacies surveyed. This may be driven by the high cost of originator brands for most of these medications, as pharmacists may tend to prioritise more affordable drugs with high turnover [29]. The OB and LPGs of salbutamol nebule and inhaler were also relatively available. These findings are corroborated by similar studies from sub-Saharan Africa, including Nigeria and Uganda, suggesting increased availability of inhaled salbutamol in pharmacies [30–32]. Salbutamol is one of the medications included in the Nigerian Essential Medicines List (EML), thereby prompting its frequent prescription and use for asthma management. This, in turn, influences pharmacies’ stocking and distribution of the medicine [33]. Conversely, other studies have reported low availability of short-acting beta-agonists in eight sub-Saharan African countries, including Ghana and Benin [34]. In a study conducted in Iran to assess the availability, pricing, and affordability of selected medicines for noncommunicable diseases, the procurement prices of the surveyed medicines were reasonable in comparison with the international reference price [35]. The World Health Organization set a voluntary target of 80% availability of affordable essential medicines, including generic, to treat major non-communicable diseases by 2025 [36]. At 80.8%, only the lowest-priced generic for Prednisolone 5 mg tablets crossed the mark. Notably, Prednisolone 5 mg tablet was the most widely available medicine in the present study, and its LPGs were more than a hundred ( > 100) times more available in community pharmacies than the originator brand. This is consistent with another study in Africa, which found an availability of up to 100% for prednisolone [30]. Factors such as low cost and preferences for oral medicines among some Nigerian populations are known to contribute to their availability [37]. Combination inhalers containing ICS/LABA were relatively scarce, and many pharmacies did not stock any generic of these medicines [13]. The availability of Budesonide inhaler, Ipratropium bromide, and Fluticasone inhaler was low, possibly due to their high cost [38]. Pharmacies may choose to stock only the OB for the few who can afford them. A cross-sectional survey of the perception of pharmacists in North-Central, Nigeria showed a high support for generic substitution and generic substitution rights for pharmacists in Nigeria [39]. In addition, infrequent prescriptions, sub-optimal knowledge, and poor awareness of international guidelines for asthma management among physicians have been found to drive poor availability of these recommended asthma medications [34, 40, 41]. A survey of healthcare workers in Africa established that lack of training, cost, out-of-stock, limited prescription, and the challenges of not having the medicines on the national EML list were major reasons for the unavailability of WHO essential medicines in healthcare facilities [30]. Again, limited pharmaceutical industries, poor government financing of pharmaceutical companies, limited investment in local production, unfavourable manufacturing conditions, and challenges in supply chain systems are among the factors affecting medicines’ availability in Nigeria [41]. Following the WHO recommendations, there is a need to invest in local production and adopt the use of quality-assured generic formulations to promote the availability of asthma medicines [19]. Affordability The affordability assessment considered both OBs and LPGs of the medications. The majority of the medicines ( > 90%) cost more than a day’s wages, indicating that the cost of asthma medications in Nigeria is high for many individuals. Specific medications, such as Salmeterol 25 mcg/Fluticasone 250 mcg inhaler, were highlighted as requiring a significant number of days’ wages to afford. Specifically, all Salmeterol/Fluticasone combination, regardless of the brand, will cost not less than a month’s worth of wages (31–51 days). Treatment of both acute and chronic illnesses remains unaffordable in many low- and middle-income countries, requiring patients to pay 0.2 to 37.0 days’ wages to purchase a single course of medicine [42]. Treatment with LPG medications could be more affordable [43]. Substantial savings could be achieved by switching private sector purchases from originator brand medicines to the lowest-priced generic equivalents [44]. The unaffordability of ICS and ICS/LABA-containing inhalers in Nigeria could be linked to scarcity [31]. Most private pharmacies do not stock maintenance inhalers due to low prescriptions by physicians, which might be linked to poor awareness of asthma guidelines on ICS in the management of asthma [37]. Consistent with other surveys, affordable medicines were generic formulations of oral corticosteroids and adrenaline injections, azithromycin 250 mg, and hydrocortisone 100 mg injections. Our findings suggest that the cost of asthma medications poses a substantial financial burden on individuals in Nigeria, potentially leading to challenges in accessing and adhering to essential asthma treatments, which could result in poorer health outcomes for individuals with asthma [30, 32, 45]. Limitations of the study and further studies This study’s limitations include its exclusive focus on data from community pharmacies. Data were only collected from retail pharmacies, neglecting information from public healthcare facilities, hospital pharmacies, and patent medicine stores, which could limit the generalisability of the findings. Future research should consider broadening the scope to encompass diverse healthcare settings, including hospitals in both public and private sectors. Further studies could include the other States of Nigeria to allow for a more robust comparative analysis between regions. Additionally, factors influencing medication availability and affordability, such as patient preferences, healthcare provider practices, and health system dynamics, were not assessed, warranting inclusion in subsequent studies for a more comprehensive understanding. In addition, the study did not explore the impact of socioeconomic factors, health insurance coverage, and other contextual variables on the accessibility of asthma medications in Nigeria. This underscores the importance of future research incorporating these aspects to gain insights into the wider socio-economic factors that affect medication access for patients with asthma. Conclusions The findings reveal high medicine prices, poor availability, and low affordability of asthma medicines. There is a need for targeted subsidies on medicines for the management of asthma, insurance reforms, and local manufacturing incentives.